Anti-androgens function to ameliorate symptomatic manifestations
associated with hyperandrogenism in PCOS, thereby addressing a cornerstone aspect of
the condition's pathophysiology. Chemically, antiandrogens are classified into steroidal
(such as spironolactone and cyproterone acetate) and nonsteroidal (including flutamide,
nilutamide, and bicalutamide). Through their antagonistic action on androgen receptors
or inhibition of androgen synthesis, antiandrogens mitigate hirsutism, acne, and
alopecia, thereby improving the quality of life and psychological well-being of PCOS
women. Additionally, studies have highlighted the profound implications of
hyperandrogenism on crucial aspects of reproductive physiology, including ovulation
dynamics, reduced pregnancy rates, risk of preterm delivery, and susceptibility to
preeclampsia, culminating in diminished rates of live births. Consequently, there is a
compelling rationale to consider that the incorporation of anti-androgen therapy may
hold promise in augmenting fertility outcomes within this patient cohort.
Keywords: Catalase, CVD, Glutathione peroxidase activity, Homocysteine, Inflammation, Insulin resistance, Lipid peroxidation, Low-grade inflammation, Malondialdehyde, Obesity, Oxidative stress, Polycystic ovarian syndrome, Reactive oxygen species, Superoxide dismutase.
